Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667587 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
A Phase 3 study of Brain Neoplasms, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 716
- Enrollment target
- 20
- Study locations
NCT02667587 is a Phase 3 study of Brain Neoplasms that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 716 participants, above the 205-participant average among 14 other Brain Neoplasms trials with a reported enrollment target (249% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02667587, a Phase 3 study of Brain Neoplasms, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 716 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Temozolomide
- RADIATION Radiotherapy
- OTHER Nivolumab Placebo
Study Locations (20)
California
- Cedars Sinai Medical Center - Los Angeles
- Local Institution - 0010 - Los Angeles
- Local Institution - 0128 - Sacramento
- Local Institution - 0029 - San Diego
- Local Institution - 0006 - San Francisco
Florida
- Local Institution - 0087 - Miami
- Local Institution - 0030 - Tampa
Massachusetts
- Local Institution - 0011 - Boston
- Local Institution - 0028 - Boston
Alabama
- Local Institution - 0023 - Birmingham
Arizona
- Local Institution - 0003 - Phoenix
Connecticut
- Local Institution - 0004 - New Haven
District of Columbia
- Local Institution - 0031 - Washington D.C.
Illinois
- Local Institution - 0022 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2024-04-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667587
The ClinicalTrials.gov registry entry for NCT02667587 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 716 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 14 other Brain Neoplasms trials with a reported enrollment target (249% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT02667587 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02667587 about?
NCT02667587 is a clinical study titled "An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)". The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation the...
What is the current status of trial NCT02667587?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 716 participants. The study started on 2016-05-09. Estimated completion is 2024-04-09.
What conditions does trial NCT02667587 study?
This clinical trial studies the following conditions: Brain Neoplasms.
What interventions are being tested in trial NCT02667587?
The interventions under investigation include: Nivolumab (DRUG), Temozolomide (DRUG), Radiotherapy (RADIATION), Nivolumab Placebo (OTHER).
Who is sponsoring clinical trial NCT02667587?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02667587 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
COMPLETED · Phase 3
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Guided Meditation During Radiation Therapy for Brain Tumors
RECRUITING · NA
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.